The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL
Peihua Lu, MD, Beijing Lu Daopei Institute of Hematology, and Hebei Yanda Lu Daopei Hospital, Langfang, China, discusses the results of a clinical trial investigating the safety and efficacy of naturally selected CD7 CAR-T cell therapy for patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma (T-ALL/T-LBL). Dr Lu first highlights the novel approach used to develop these CAR-T cells, and then provides an overview of the results from this trial and the overall efficacy of this agent. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
